NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
68788-1823-01 | 68788-1823 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Apr 28, 2011 | May 10, 2011 | No Longer Used | |
42291-0458-30 | 42291-0458 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | May 15, 2025 | In Use | |
68071-3028-02 | 68071-3028 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Mar 14, 2017 | In Use | |
68071-3713-03 | 68071-3713 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Oct 25, 2024 | In Use | |
57881-0444-10 | 57881-0444 | Ondansetron | Zuplenz | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Oct 8, 2014 | In Use | |
17478-0547-01 | 17478-0547 | Granisetron Hydrochloride | Granisetron Hydrochloride | 0.1 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Oct 1, 2009 | In Use | |
60760-0637-20 | 60760-0637 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Mar 13, 2018 | Dec 31, 2021 | In Use |
62778-0072-01 | 62778-0072 | Granisetron Hydrochloride | Granisetron Hydrochloride | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Dec 23, 2009 | Dec 23, 2009 | No Longer Used | |
68788-9368-08 | 68788-9368 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Aug 27, 2014 | Apr 28, 2015 | In Use |
54868-5089-00 | 54868-5089 | Ondansetron | Zofran ODT | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jun 9, 2004 | Jun 30, 2011 | No Longer Used | |
66758-0035-01 | 66758-0035 | Granisetron | Granisetron | 1.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Jun 30, 2008 | May 19, 2020 | No Longer Used |
50090-1600-05 | 50090-1600 | ondansetron hydrochloride | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan 5, 2015 | Mar 31, 2018 | In Use |
63629-4093-01 | 63629-4093 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jun 3, 2009 | In Use | |
70518-3716-00 | 70518-3716 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Apr 16, 2023 | In Use | |
63629-4014-09 | 63629-4014 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Aug 9, 2012 | In Use | |
83008-0074-30 | 83008-0074 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jul 25, 2024 | Jan 31, 2028 | In Use |
00781-3415-75 | 00781-3415 | Palonosetron Hydrochloride | Palonosetron Hydrochloride | 0.25 mg/5mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Nov 26, 2018 | In Use | |
50090-1600-01 | 50090-1600 | ondansetron hydrochloride | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan 5, 2015 | Jan 31, 2018 | In Use |
00078-1098-94 | 00078-1098 | asciminib | SCEMBLIX | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ABL/BCR-ABL1 | Oral | Oct 29, 2021 | In Use | |
00078-1196-20 | 00078-1196 | Asciminib | SCEMBLIX | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ABL/BCR-ABL1 | Oral | Apr 18, 2024 | In Use | |
00078-1091-94 | 00078-1091 | asciminib | SCEMBLIX | 20.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ABL/BCR-ABL1 | Oral | Oct 29, 2021 | In Use | |
00078-1091-20 | 00078-1091 | asciminib | SCEMBLIX | 20.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ABL/BCR-ABL1 | Oral | Oct 29, 2021 | In Use | |
00078-1098-30 | 00078-1098 | asciminib | SCEMBLIX | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ABL/BCR-ABL1 | Oral | Oct 29, 2021 | In Use | |
00078-1098-20 | 00078-1098 | asciminib | SCEMBLIX | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ABL/BCR-ABL1 | Oral | Oct 29, 2021 | In Use | |
68727-0712-01 | 68727-0712 | Lurbinectedin | ZEPZELCA | 0.5 mg/mL | Chemotherapy | Alkylating Agent | Adduct Forming Agent | Intravenous | Jun 15, 2020 | In Use |
Found 11564 results — Export these results